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ABSTRACT
Introduction: Lupus nephritis (LN) in pediatric
systemic lupus erythematosus (pSLE) requires
treatment with corticosteroids (CS) and
mycophenolate mofetil (MMF) or
cyclophosphamide (CYC). However, some
patients fail standard therapy leaving
physicians with few options. Although two
recent phase II/III randomized controlled trials
using abatacept (ABA) with and without MMF
in adult SLE did not meet their endpoints, we
examined if this combination therapy may have
a therapeutic benefit in pSLE patients with
refractory class IV and V LN.
Methods: We performed a retrospective chart
analysis of five pSLE patients with class IV and V
LN. All patients were treated with ABA ? MMF
after previous failure to CYC and MMF. CS doses
and SLE Disease Activity Index (SLEDAI) score
were assessed at diagnosis and after 12 and
24 weeks of each treatment.
Results: Patient age at diagnosis was 9–15 years
(mean 12.6 ± 2.3). Average disease duration
before initiation of ABA ? MMF therapy was
22–97 months (mo) (mean 52.8 ± 30.8).
Treatment with ABA ? MMF resulted in an
improvement in SLEDAI score and reduction
in CS dose by 12 weeks in all five patients. One
patient achieved complete remission and three
patients were weaned off steroids after 7–20 mo
(mean 13 ± 6.5). Repeated measures analysis of
variance showed significant change from
SLEDAI at time of diagnosis (baseline) over
24 weeks of treatment with CYC (P = 0.0013)
and with ABA ? MMF (P\0.0001). Paired
comparison to baseline SLEDAI scores showed
some decrease after 12 weeks of treatment with
MMF monotherapy (P = 0.0520).
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Conclusion: The data suggest that combination
therapy with ABA ? MMF may be an alternative
option in refractory pSLE nephritis. Additional
studies are needed in pSLE to further assess the
efficacy of this combination treatment.
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INTRODUCTION
Pediatric systemic lupus erythematosus (pSLE)
with class IV/V lupus nephritis (LN) often
requires treatment with corticosteroids (CS)
and other agents such as azathioprine (AZA),
methotrexate (MTX), mycophenolate mofetil
(MMF), or cyclophosphamide (CYC) [1, 2].
Although the 5-year survival rate exceeds 95%,
the disease may remain intractable in some
children [3] and new treatment modalities must
sometimes be explored.
Abatacept (ABA) is a recombinant fusion
protein that acts by competing with CD28 for
binding to CD80/CD86, and inhibits its
engagement on T cells and plasma cells [4].
Because both T and B cells play an active role in
SLE, it was postulated that ABA could be
beneficial in SLE. Several studies in murine
models of SLE have shown improvement in
both SLE and nephritis activity either with
CTLA-4Ig alone or in combination with CYC
[5, 6]. Although recent controlled trials of ABA,
with and without combination treatment with
MMF for adult SLE, did not meet their primary
or secondary endpoints, exploratory analyses
suggested efficacy in some subgroups [7, 8].
ABA is currently FDA approved for treatment
of juvenile idiopathic arthritis (JIA) and
rheumatoid arthritis, however, its use in pSLE
has not been reported [9]. This small case series
examines ABA in conjunction with MMF as a
potentially effective treatment for pSLE in a
subset of children who have failed other
medications.
MATERIALS AND METHODS
We performed a retrospective analysis of
children with pSLE, with class IV and V LN
diagnosed by pathology at Children’s Hospital
Los Angeles, Los Angeles, CA, USA. Patients met
at least 4 of the 11 American College of
Rheumatology (ACR) criteria for a diagnosis of
SLE [10]. All patients received and/or failed
treatment with CYC at a daily oral dose of 2 mg/
kg/dose, bi-weekly dose infusion of 10 mg/kg/
dose or monthly infusion of 1,000 mg/m2, MMF
monotherapy at a dose of 600–1,000 mg/m2/
dose given twice daily (bid) or rituximab (RTX)
750 mg/m2 two doses given 2 weeks apart. Some
patients received additional therapeutic
interventions with azathioprine (AZA) and
cyclosporine (CSA). After an inadequate
response to the above therapy, combination
therapy with ABA and MMF (ABA ? MMF) was
started. Using the SLEDAI scoring system which
assigns an index score based on the presence or
absence of 24 abnormalities associated with SLE
(in 9 organ systems) with scores assigned as
follows; 8 for central nervous system
involvement and vasculitis, 4 for renal disease
and musculoskeletal, 2 for serosal, dermal and
immunologic and 1 for constitutional and
hematologic. The higher the score, the more
disease involvement [11]. The analyzed data
points were assigned a (SLEDAI) score at time of
diagnosis (referred to as baseline) and then 12
and 24 weeks into each treatment. These data
points are separated in time by several years in
some cases with minimal overlap of RTX or CYC
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treatment with the combination therapy. All
patients received at least 4 doses of ABA (10 mg/
kg/dose every 2 weeks for 3 doses, then every
4 weeks) in addition to CS. Patients with
hypogammaglobulinemia also received
replacement IVIG at 0.5 g/kg monthly at the
discretion of the treating physician.
Institutional review board approval and
informed consent were obtained as
appropriate. All procedures followed were in
accordance with the ethics standards of the
responsible committee on human
experimentation (institutional and national)
and with the Helsinki Declaration of 1975, as
revised in 2000 and 2008.
Statistical Analysis
Data collected included demographics,
medications, laboratories, clinical findings,
and adverse events. The pattern of change in
SLEDAI scores from time of diagnosis, after 12
and 24 weeks of each treatment, was evaluated
with repeated measures analysis of variance
(ANOVA), for each drug, using SAS/STAT v
9.2 statistical software (SAS institute Inc., SAS
Campus Drive, Cary, NC 27513, USA) with
P\0.05 considered statistically significant.
CASE PRESENTATION
Patient 1 is a white male diagnosed with pSLE at
age 14 years based on the positive antinuclear
antibodies (ANA), double-stranded DNA
(dsDNA), antiphospholipid antibodies (APL),
glomerulonephritis (GN) (class IV/V),
cytopenias, arthritis, vasculitis and malar rash.
SLEDAI score at diagnosis was 32 (Fig. 1), and
initial steroid dose was 90 mg daily. He had
several complications, including pulmonary
embolus and hemorrhage, and splenic
infarction for which he was on subcutaneous
enoxaparin. The treatment included 12
monthly infusions of CYC 1,000 mg/m2, AZA,
2 RTX doses (750 mg/m2 every 2 weeks for two
doses), tacrolimus and MMF 600 mg/m2/dose
bid. Owing to persistent disease activity, he
remained on CS 30 mg daily for 12 mo until it
was increased to 60 mg daily because of disease
flare prior to initiating ABA ? MMF.
ABA ? MMF were started 25 mo after diagnosis
due to active GN and cytopenias. At 12 weeks of
combination therapy, ABA ? MMF, SLEDAI
score decreased to 8 with resolution of urinary
casts, hematuria, rash and thrombocytopenia,
negative dsDNA (20–8 IU/ml), though CS dose
remained unchanged at 60 mg daily. At
24 weeks of combination therapy, SLEDAI
decreased to 6 with normalization of
complement C3 (C3) (42–103 mg/dl),
improved creatinine (4.2–1.8 mg/dl), and urine
protein to creatinine ratio (UPC) (2.6–0.7);
urine with no casts or active sediment and no
clinically active disease. At this time, CS dose
was 40 mg daily. The patient then transitioned
to adult rheumatology care, at which time he
was clinically stable.
Patient 2 is a Hispanic female diagnosed with


















































Fig. 1 SLEDAI score per patient
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dsDNA, GN (class IV/V), cytopenias, and
arthritis. SLEDAI score at diagnosis was 19. She
was initially treated with CS 30 mg daily and
MMF 750 mg/m2 bid. MMF monotherapy was
stopped and daily CYC 2 mg/kg/dose was
started at 37 mo after diagnosis due to new
onset interstitial lung disease and worsening
GN as evidenced by increasing proteinuria and
urinary casts. RTX 750 mg/m2 every 2 weeks for
2 doses were given in addition to CYC 60 mo
after diagnosis due to continued disease
activity; however, because of persistent
cytopenia and recurrent infections, CYC was
replaced with MMF 750 mg/m2/dose bid.
Although on MMF her disease flared and CS
dose was increased to 90 mg daily. ABA ? MMF
was then started 63 mo after diagnosis due to
active GN, cytopenias, and low complements.
At 12 weeks of ABA ? MMF her UPC decreased
(57.7–0.7), thrombocytopenia resolved
(64,000–238,000 k/ll), and C3 normalized
(60–149 mg/dl). She also had improvement in
white blood cells (WBC) from 3.4–11.6 k/ll and
hemoglobin (HgB) from 6.9 to 8.6 g/dl. At 12
and 24 weeks of ABA ? MMF combination
therapy her SLEDAI score was 4 due to mild
proteinuria. CS dose was decreased to 30 mg
daily by 24 weeks. At this time, she was
clinically stable and transitioned into adult
rheumatology care.
Patient 3 is an African American female
diagnosed with pSLE at age 13 years based on
positive ANA, dsDNA, GN (IV), serositis, malar
rash, cytopenias, arthritis, and photosensitivity.
At diagnosis SLEDAI score was 28 and CS dose
60 mg daily. She had a complicated course with
recalcitrant disease that included recurrent
pleural effusions requiring pleurodesis. Several
therapies including MTX, CSA, MMF 1,000 mg/
m2/dose bid, RTX 750 mg/m2 for 2 doses, CYC
2 mg/k/day and nitrogen mustard were
ineffective as evidenced by persistent
hypocomplementemia, arthritis, and elevated
UPC with urine casts. At 12 weeks of MMF
1,000 mg/m2/dose monotherapy, CS dose had
been increased to 90 mg. Owing to persistent
SLE activity; ABA was started 57 mo after
diagnosis in conjunction with MMF. By
12 weeks of this therapy, her SLEDAI score had
decreased to 10, UPC improved (23.2–10) and
C3 normalized (39–80 mg/dl). In addition, her
abnormal urinary sediment (cast, WBC, RBC),
alopecia and pleurisy resolved and CS had been
weaned to 40 mg daily. At 24 weeks, she had
further improvement with a SLEDAI score of 6,
C3 of 134, dsDNA of 46 IU/ml (decreased from
[200 IU/ml), resolution of arthritis, stabilized
GN with UPC of 2.5, and CS dose of 30 mg
daily.
Patient 4 is a Hispanic female who was
diagnosed with pSLE at age 12 years based on
positive ANA, dsDNA, GN (IV), cytopenias,
arthritis, and malar rash. SLEDAI score at
diagnosis was 26 and initial CS dose 90 mg
daily. In addition, she had menorrhagia with
factors II and VIII antibodies. She was treated
with daily oral CYC 2 mg/kg/dose for 18 mo,
RTX 750 mg/m2 every 2 weeks for two doses due
to persistent disease and MMF 750 mg/m2/dose
bid monotherapy. She had progressive GN and
persistent arthritis, rash, low complements, and
hypogammaglobulinemia. ABA was added to
MMF monotherapy 22 mo after diagnosis. At
12 weeks of combination therapy ABA ? MMF,
her SLEDAI score had decreased to 8, dsDNA
was negative, UPC markedly decreased
(6.38–0.69), C3 normalized (70–106 mg/dl)
and she had resolution of arthritis, rash, oral
ulcers, cytopenia, hematuria and casts. CS dose
at this time was 20 mg daily. Data were not
available at 24 weeks as she had been
transitioned to another provider.
Patient 5 is an Asian female diagnosed with
pSLE at age 9 years based on the positive ANA,
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dsDNA, GN (V), and cytopenias. SLEDAI score at
diagnosis was 26 and initial CS dose was 60 mg
daily. She was treated with monthly CYC
1,000 mg/m2 monthly infusion for 21 mo,
RTX 750 mg/m2 for two doses, AZA, and then
MMF 750 mg/m2/dose bid, but without
sustained improvement. Owing to persistent
proteinuria and low complements, ABA was
started 97 mo after diagnosis in conjunction
with MMF; by 12 weeks of ABA ? MMF therapy
her SLEDAI decreased to 12, C3 increased from
40 to 80 mg/dl, dsDNA decreased from 657 to
280 IU/ml, and CS decreased to 10 mg daily. By
24 weeks of ABA ? MMF therapy, SLEDAI score
was 2 with resolution of proteinuria, pyuria and
normalization of C3, although the dsDNA was
persistently positive at 146 IU/ml. Her clinical
condition remains stable to date.
Table 2 Outcome measures at baseline, 12 and 24 weeks of treatment
Measurable outcome Baseline mean 12 week mean 24 week mean
SLEDAI score 19–32 (26.2 ± 31)
SLEDAI on CYC 8–16 (13.6 ± 3.5) 4–16 (10.4 ± 4.7)
SLEDAI on MMF 11–26 (20.6 ± 6.7) 12–20 (16 ± 4)
SLEDAI on ABA ? MMF 4–12 (8.4 ± 2.9) 2–6 (4.5 ± 1.9)
C3 Baseline 15–162 (54.5 ± 60.6)
C3 on CYC 75–104 (90.4 ± 10.3) 76–105 (89.4 ± 12.3)
C3 on MMF 22–143 (72 ± 47) 38–59 (45.6 ± 11.5)
C3 on ABA ? MMF 75–149 (98 ± 31) 86–165 (125 ± 36.7)
dsDNA baseline 47–640 (311 ± 283.8)
dsDNA on CYC 30–200 (84.4 ± 154) 42–200 (109.2 ± 74)
dsDNA on MMF 6–236 (129.6 ± 96) 20–308 (176 ± 145.4)
dsDNA on ABA ? MMF 0–280 (63.8 ± 121.5) 0–111 (43 ± 51.2)
UPC baseline 0.34–22 (10.96 ± 9.5)
UPC on CYC 0.06–3.7 (1.5 ± 1.34) 0.15–11 (3.0 ± 4.5)
UPC on MMF 0.7–23.2 (6.44 ± 9.66) 0.09–2 (1.09 ± 0.9)
UPC on ABA ? MMF 0.69–10 (3.08 ± 4) 0.2–3.32 (1.23 ± 1.4)
CS dose baseline 30–90 (66 ± 25)
CS dose on CYC 10–70 (44 ± 24) 7.5–40 (26.5 ± 13.8)
CS dose on MMF 20–90 (47 ± 33) 10–90 (40 ± 43.5)
CS dose on ABA ? MMF 10–60 (38 ± 22.8) 0–40 (25 ± 17.3)
Data presented are min–max (mean ± SD)
ABA abatacept, C3 complement C3, CS corticosteroids, CYC cyclophosphamide, dsDNA double-stranded DNA, MMF
mycophenolate mofetil, SLEDAI Systemic Lupus Erythematosus Disease Activity Index, UPC urine protein to creatinine
ratio
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RESULTS
Patient age at diagnosis was 9–15 years (mean
12.6 ± 2.3). Average disease duration prior to
ABA ? MMF therapy was 22–97 mo (mean
52.8 ± 30.8). Two patients had class IV LN,
one patient had class V LN and two patients had
class IV/V LN. All patients had tried and failed
therapy with several other immunosuppressive
agents, including CYC and MMF. Four of the
five patients were on a minimum of 2 mg/kg/
day of CS at time of diagnosis (Table 1).
Mean SLEDAI scores at time of diagnosis
(baseline) and after 12 and 24 weeks of each
therapy are shown in Table 2. Baseline SLEDAI
scores were significantly elevated with the
lowest score being 19 (Fig. 1). Mean dose of
steroids, levels of dsDNA, C3 level and UPC are
also listed in Table 2.
At 12 weeks of ABA ? MMF all 5 patients had
a decrease in their SLEDAI scores (Figs. 1, 2) and
successfully had their CS dose reduced (Table 1;
Fig. 3). Data were not available at 24 weeks for
two of the five patients after taking MMF
monotherapy and for one patient after taking
ABA ? MMF combination therapy, due to
transition of care. One patient achieved
complete remission and three patients were
able to discontinue steroids after 7–20 mo
(mean 13 ± 6.5) (Table 1) on ABA ? MMF
combination therapy.
Repeated measures ANOVA for patients with
data at all three time points revealed significant
decreases in SLEDAI scores for five patients after
taking CYC (P = 0.0013) and for four patients
after taking ABA ? MMF (P\0.0001). Post hoc
pairwise comparisons to baseline at 12 and
24 weeks were significant for both drugs
(P = 0.02 and P = 0.006, respectively, for CYC;
P = 0.002 and P = 0.0006, respectively, for
ABA ? MMF). Since only three patients had
SLEDAI scores after 24 weeks on MMF,
repeated measures ANOVA was not used for
this drug; however, five patients showed some
decrease in scores after 12 weeks on MMF
(paired t test P = 0.0520).
DISCUSSION
The use of ABA with MMF resulted in
improvement in complement (Fig. 4), dsDNA
levels (Fig. 5) and blood counts (CBC) in all five
patients despite the previous failure with CYC
and MMF monotherapy. Furthermore, it
permitted the reduction in the CS dose. UPC
improved with all three therapeutic
interventions (Fig. 6) which is consistent with
previous studies evaluating the use of CYC and












































Fig. 3 Clinical response by CS reduction
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mean UPC at 12 weeks, the response with CYC
was more notable than at 12 weeks with MMF
monotherapy or ABA ? MMF, but by 24 weeks
MMF monotherapy was comparable to
ABA ? MMF combination therapy and better
than CYC monotherapy (Table 2). All patients
responded with significant decrease in their
SLEDAI scores while on ABA ? MMF.
Replacement IVIG was given to two patients
for hypogammaglobulinemia. No significant
adverse events were observed while on
ABA ? MMF therapy over a median of 15.5
(interquartile range 7.5–19.25) doses.
All patients had recalcitrant disease that had
been aggressively treated with several other
medications without adequate response prior
to ABA ? MMF treatment. The influence of
noncompliance with MMF producing these
findings is difficult to determine. However,
mycophenolic acid levels and mycophenolic
acid glucoronide levels (normal range 1–3.5 and
35–100 mcg/ml, respectively) measured in four
of the five patients during MMF monotherapy
were within therapeutic range. Although MMF
alone has been shown to be as effective as CYC
in adult studies [12], these studies have not
been replicated in children. This study
demonstrated that combination therapy with
ABA ? MMF was more effective than that of
CYC and MMF monotherapy for this group of
patients. ABA, particularly in combination with
MMF, may be efficacious in treatment-
refractory pSLE, including those with
glomerulonephritis. Further prospective studies
of ABA combo treatment in pSLE are needed to
substantiate these findings.
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Fig. 6 Clinical response by proteinuria (urine protein/
creatinine ratio)
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